Understanding Response Time for Patients With AML Using Drug Treatment Combo

Brian Jonas, MD, PhD, associate professor of medicine at the University of California at Davis School of Medicine and UC Davis Comprehensive Cancer Center, discusses recent data presented at ASCO 2020, including use of combination therapy with Venclexta (venetoclax) for the treatment of acute myeloid leukemia. 

About the speaker:

Dr. Brian Jonas is an Associate Professor of Medicine at the University of California at Davis School of Medicine and UC Davis Comprehensive Cancer Center (UCDCCC). He completed his undergraduate studies at the University of California at Berkeley and his MD and PhD degrees at UC Davis. Dr. Jonas completed internship and residency at Stanford University. He completed his fellowship in Hematology and Oncology at Stanford University, and he completed a postdoctoral fellowship in the laboratory of Dr. Ravi Majeti. His clinical and research focus is in acute myeloid leukemia, myelodysplastic syndromes (MDS), other myeloid malignancies, and acute lymphoblastic leukemia. Dr. Jonas leads Acute Leukemia and MDS research at the UCDCCC, and he is the Chair of the UCDCCC Hematologic Malignancies Working Group. He is an active member of ASH. Dr. Jonas is a founding member of the UC Hematologic Malignancies Consortium and a member of the SWOG Leukemia Committee.